Aller au contenu principal
Profil bibliographique

Marcos Vidal-Manrique

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

10Publications signalées
125Citations signalées
3Affiliations récentes

Les institutions déclarées

Les domaines associés

Immune Cell Function and InteractionCAR-T cell therapy researchT-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersHematopoietic Stem Cell Transplantation

Les publications récentes

Accès ouvert 2026 article OpenAlex

Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition

Marcos Vidal-Manrique, Laura Hooijmaijers, Julia A.J. Teders, Elif Saf et autres

Adoptive Natural Killer (NK) cell transfer is a promising therapy for the treatment of cancer. We developed a GMP-compliant protocol to generate NK cells from hematopoietic stem and progenitor cells (HSPC-NK). However, the immunosuppressive tumor microenvironment - especially prostaglandin E2 (PGE2) signaling …

nl, us (code pays fourni par la source)

0 citations Frontiers in Immunology
Accès ouvert 2025 article OpenAlex

Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull mice

Laura Hooijmaijers, Marcos Vidal-Manrique, Bart Spils, Diede van Ens et autres

The adoptive transfer of natural killer (NK) cells represents a promising cancer therapy due to their intrinsic ability to distinguish between malignant and healthy cells in an allogeneic context, enabling off-the-shelf manufacturing possibilities. On demand availability of cryopreserved advanced therapy medicinal products …

nl (code pays fourni par la source)

6 citations Cellular and Molecular Life Sciences
Accès ouvert 2025 article OpenAlex

IL-15 transpresentation by ovarian cancer cells improves CD34 + progenitor-derived NK cell's anti-tumor functionality

Marcos Vidal-Manrique, Thomas Nieuwenstein, Laura Hooijmaijers, Paul K.J.D. de Jonge et autres

Ovarian cancer (OC) is the most lethal gynecological malignancy. As high numbers of Natural Killer (NK) cells in ascites associate with improved survival, the adoptive transfer of allogeneic NK cells is an attractive therapeutic strategy. An approach to further improve NK cell …

nl, us, bh (code pays fourni par la source)

11 citations OncoImmunology
Accès ouvert 2024 article OpenAlex

EP2/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s

Jorge Cuenca‐Escalona, Johanna Bödder, Beatriz Subtil, Marta Sánchez‐Sánchez et autres

Tumor-derived prostaglandin E2 (PGE2) impairs antitumor immunity by priming suppressive functions on various immune cell types, including dendritic cells (DCs). In this way, tumors mediate DC dysfunction and hamper their antitumoral activity. PGE2 is known to modulate DC function via signaling through …

nl, us, de (code pays fourni par la source)

14 citations Journal of Leukocyte Biology
Accès ouvert 2023 article OpenAlex

Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity

P.M.M. van Hauten, Laura Hooijmaijers, Marcos Vidal-Manrique, Anniek B. van der Waart et autres

Background aims Natural killer (NK) cell transfer is a promising cellular immunotherapy for cancer. Previously, we developed a robust method to generate large NK cell numbers from CD34 + hematopoietic stem and progenitor cells (HSPCs), which exhibit strong anti-tumor activity. However, since …

nl, us (code pays fourni par la source)

9 citations Cytotherapy
Accès ouvert 2023 article OpenAlex

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide

Maria Karvouni, Marcos Vidal-Manrique, Katharina H. Susek, Alamdar Hussain et autres

Background aims Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of …

se, us (code pays fourni par la source)

11 citations Cytotherapy
Accès ouvert 2022 article OpenAlex

Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37

Rens Peeters, Jorge Cuenca‐Escalona, Esther A. Zaal, Anna T. Hoekstra et autres

The importance of fatty acid (FA) metabolism in cancer is well-established, yet the mechanisms underlying metabolic reprogramming remain elusive. Here, we identify tetraspanin CD37, a prognostic marker for aggressive B-cell lymphoma, as essential membrane-localized inhibitor of FA metabolism. Deletion of CD37 on …

nl, de (code pays fourni par la source)

38 citations Nature Communications
Accès ouvert 2022 article OpenAlex

Engineered NK Cells Against Cancer and Their Potential Applications Beyond

Maria Karvouni, Marcos Vidal-Manrique, Andreas Lundqvist, Evren Alici

century and has since resulted in multiple breakthroughs in different fields of medicine, such as neurology, cardiology, and oncology. Lately, cell and gene therapy are merging to provide cell products with additional or enhanced properties. In this context, adoptive transfer of genetically …

se (code pays fourni par la source)

36 citations Frontiers in Immunology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.